Next, we drew KM curves of the risk score signature stratified by IDH-mutant status, 1p/19q codeletion, MGMT promoter methylation, age, and WHO grade in the glioma patients of the training and validation cohorts. This evidence concerns the gene MGMT and central nervous system cancer.